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ABSTRACT: Kinases are frequently studied in the context of
anticancer drugs. Their involvement in cell responses, such as
proliferation, differentiation, and apoptosis, makes them interesting
subjects in multitarget drug design. In this study, a workflow is
presented that models the bioactivity spectra for two panels of
kinases: (1) inhibition of RET, BRAF, SRC, and S6K, while
avoiding inhibition of MKNK1, TTK, ERK8, PDK1, and PAK3,
and (2) inhibition of AURKA, PAK1, FGFR1, and LKB1, while
avoiding inhibition of PAK3, TAK1, and PIK3CA. Both statistical
and structure-based models were included, which were thoroughly
benchmarked and optimized. A virtual screening was performed to
test the workflow for one of the main targets, RET kinase. This
resulted in 5 novel and chemically dissimilar RET inhibitors with remaining RET activity of <60% (at a concentration of 10 μM) and
similarities with known RET inhibitors from 0.18 to 0.29 (Tanimoto, ECFP6). The four more potent inhibitors were assessed in a
concentration range and proved to be modestly active with a pIC50 value of 5.1 for the most active compound. The experimental
validation of inhibitors for RET strongly indicates that the multitarget workflow is able to detect novel inhibitors for kinases, and
hence, this workflow can potentially be applied in polypharmacology modeling. We conclude that this approach can identify new
chemical matter for existing targets. Moreover, this workflow can easily be applied to other targets as well.
■ INTRODUCTION
Compound promiscuity can be leveraged to develop multi-
target drugs. Such multitarget drugs can replace existing
multidrug treatments, while maintaining the therapeutic
effect.1 One of the advantages of a multitarget drug or
single-drug treatment is that no drug−drug interactions occur,
making the treatment less risky and harmful for the patient.2
However, since multitarget drugs are designed to bind to
multiple proteins, they may tend to be more promiscuous as
well. Therefore, when developing multitarget compounds, off-
target binding and pathways should also be considered.
In the light of the “Multi-Targeting Drug” DREAM
challenge,3 bioactivities were computationally modeled for
two panels of kinases. The first panel was based on treatment
of medullary thyroid carcinoma, where kinases RET, BRAF,
SRC, and S6K, should be inhibited and MKNK1, TTK, ERK8,
PDK1, and PAK3, should not be affected.4,5 RET was
considered the main on-target kinase in this panel and, thus,
was prioritized over other kinases in the panel. The second
panel was based on tauopathies in neurogenerative disease:
compounds should inhibit AURKA, PAK1, FGFR1, and LKB1
and not bind to PAK3, TAK1, and PIK3CA.3 Since the main
on-targets, AURKA and PAK1, and additional on-targets
FGFR1 and LKB1, are targeted in the central nervous system,
compounds for panel 2 kinases should additionally be able to
pass the blood−brain barrier.
This study describes a rigorous workflow to model the
bioactivity spectra of compounds in kinases (Figure 1) and
identify novel inhibitors. Every step in the workflow was
extensively benchmarked, and each model was validated prior
to virtual screening. A consensus scoring approach was used to
rank virtual screening compounds, and only compounds with a
Tanimoto similarity (ECFP6 (extended-connectivity bit string,
diameter 6))6 < 0.4 were considered to make sure that existing
active molecules would not be “rediscovered”. This consensus
approach encompassed statistical modeling techniques, such as
quantitative structure−activity relationship (QSAR) models
and proteochemometric (PCM) modeling.7−9 Moreover,
structure-based docking and pose metadynamics were
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applied.10 Next to compound ranking, this approach was also
used to exclude inactive-predicted compounds from virtual
screening along the way. Fast machine learning models were
applied to discard compounds early in the workflow.
Subsequently, slower, but information rich, structure-based
models were applied that consequently only had to score a
smaller fraction of compounds compared to the entire initial
virtual screening set. In this way, millions of compounds were
screened rapidly and scored accurately.
In addition to the extensive benchmark validations, the
workflow was also validated in vitro for one of the main on-
target kinases. Forty-six compounds were experimentally
validated for RET, of which 15 were selected based on the
consensus approach, 6 based on statistical models only, and 25
compounds based on structure-based modeling. This resulted
in a total of 5 inhibitors causing RET activity < 60% at a
concentration of 10 μM. The four most potent compounds
were further inspected and their IC50 were determined.
Although the most potent RET inhibitor was modestly active
with a pIC50 of 5.1 ± 0.1, all compounds were chemically
distinct from known RET inhibitors with Tanimoto (ECFP6)
similarities smaller than 0.29. Therefore, the identified
inhibitors in this study provide a new starting point for hit/
lead optimization based on novel scaffolds.
■ RESULTS
Data Curation and Filtering. Compound bioactivity data
was derived from different sources to increase data availability
for the benchmark sets in model training and validation. Kinase
compound data was retrieved from the following sources:
ChEMBL database (version 23),11 publicly available sets from
Eidogen,12 and ExCAPE-DB.13 The data was curated by
standardizing chemical structures and bioactivity values (see
Methods section for details). In this way, a data set was
constituted that contained compound bioactivity information
for 512 kinases (data set available at 10.4121/uuid:6af1d9de-
281f-4221-b7e1-e7c01b90dfe0). This data set was used for
training and testing of statistical models. Since validation was
performed using cross-validation, the data set was divided into
subsets; five subsets were created based on chemical clustering
of the compounds per target (see Methods section for details).
The biggest subset was used in training of every model,
whereas the remaining four subsets were used rotationally for
testing. The subsets that were not used in testing in the specific
iteration were added to the training set.
Additionally, separate active/inactive/decoy data sets were
constructed for validation of structure-based models. These
benchmark sets were constructed for each panel kinase
separately. Data for these benchmark sets were derived from
ChEMBL (version 23), which was curated and filtered to
construct a benchmark set for each kinase containing inactive
and chemically diverse active compounds: only compounds
with measured pChEMBL14 values were included in the
benchmark sets and a restrain was set for the number of active
Figure 1. Virtual screening workflow for the two panels of kinases.
Statistical models (blue), structure-based models (green), and
molecular dynamics (orange) were applied to rank the virtual
screening compounds.
Table 1. PCM Performance Per Targeta
PCM QSAR number of compounds
target MCC BEDROC (α = 20) ROC MCC BEDROC (α = 20) ROC active (pChEMBL ≥ 6.5) inactive (pChEMBL < 6.5)
RET 0.15 0.64 0.76 0.23 0.63 0.75 1492 416
BRAF 0.18 0.74 0.56 0.20 0.75 0.54 1119 1359
SRC 0.28 0.47 0.72 0.26 0.47 0.72 4642 2238
S6K 0.38 0.85 0.79 0.45 0.85 0.78 1662 685
MKNK1 0.09* 0.42 0.61 0.01 0.32 0.50 549 51
TTK1 0.22 0.45 0.78 0.26 0.44 0.75 663 276
ERK8 **** 0.05 0.48 −0.12 0.02 0.35 302 30
PDK1 0.27* 0.85 0.72 0.31 0.86 0.71 579 536
PAK3 0.25 0.72 0.91 0.07 0.27 0.71 1204 53
AURKA 0.37 0.65 0.78 0.38 0.47 0.77 3165 1674
PAK1 0.32 0.74 0.86 0.28 0.66 0.77 712 114
FGFR1 0.41 0.70 0.85 0.77 0.71 0.82 2477 928
LKB1 0.57** 0.53 0.76 0.26* 0.45 0.63 429 47
TAK1 0.15*** 0.27 0.68 0.12* 0.33 0.69 1204 53
Average 0.25 0.58 0.74 0.25 0.52 0.68 295 56
aMean over 4-fold cross-validation. Asterisks indicate that no value could be determined due to lack of predicted (positive/negative) classes: *, 1
cross-validation failed; **, 2 cross validations failed; ***, 3 cross validations failed; ****, 4 cross validations failed. Indicated in bold in each
column is the best performing model for that given parameter.
Journal of Chemical Information and Modeling pubs.acs.org/jcim Article
https://dx.doi.org/10.1021/acs.jcim.9b01204
J. Chem. Inf. Model. XXXX, XXX, XXX−XXX
B
compounds. Up to a maximum of 100 actives per kinase were
included, whereas the number of inactive compounds was not
limited. The 100 active compounds were selected based on
chemical diversity by clustering the compounds with
pChEMBL value >6.5 into 100 clusters and selecting only
the cluster centers. Additionally, DUD-E15 decoys were added
to each benchmark set. These decoys have similar
physicochemical properties as active ligands but differ in
chemical structure. The structure-based benchmark sets were
smaller than the training and test sets of statistical models, but
big enough to allow for validation of the models. The smaller
size of the structure-based benchmark sets allowed for quicker
model evaluation, resulting in validation of many protein
structures.
The virtual screening set that was screened using both
statistical- and structure-based models was derived from the
ZINC1516 database. All “in stock” compounds were filtered on
drug-like properties by discarding compounds that did not
adhere to 3 of 4 Lipinski rules.17 Furthermore, compounds
were filtered on novelty: compounds with Tanimoto similarity
(ECFP6) > 0.4 compared to existing actives (pChEMBL > 5)
on the kinases in the respective panel were excluded from the
virtual screening set. The virtual screening set was additionally
filtered for panel 2 kinases by including the likelihood of
compound passing the central nervous system by only keeping
compounds with polar surface area < 75 Å2. This resulted in a
virtual screening set for panel 1 of 11 168 736 compounds and
for panel 2 of 5 126 312 compounds.
Statistical Models. Separate quantitative structure−
activity relationship (QSAR) models were constructed for
the main on-targets RET, AURKA, and PAK1, as a first filter
for bioactive compounds. The models were validated with 4-
fold cross-validation using standardized benchmark sets (see
Methods for details). The benchmark sets were constructed
per target and were extracted from the main statistical
benchmark set containing 512 kinases. Chemical descriptors
were calculated for every compound: FCFP4 (feature-
connectivity bit string, diameter 4) fingerprints and phys-
icochemical descriptors (listed in Table S2). These descriptors
describe the compounds and were used in training the models.
The RET, AURKA, and PAK1 QSAR models were predictive
with ROC (receiver operating characteristic) scores higher
than random (Table 1). The ROC of the QSAR models was
comparable between targets (ROC 0.76 ± 0.01), whereas the
Matthews correlation coefficient (MCC) varied slightly more
(MCC 0.30 ± 0.08).
The performances of the QSAR models were sufficient as a
first filter for bioactive compounds, discarding the least active
compounds and steering clear of the decision boundary.
Virtual screening set 1 was screened using the RET QSAR, and
virtual screening set 2 was screened using the AURKA and
PAK1 QSAR models separately. Using the active class
probability score, the most promising compounds (250 000
compounds per RET/AURKA/PAK1) were selected to be
further processed in the structure-based approaches. This
prescreening of compounds with a simple, but fast model
decreased the number of compounds effectively. As a result,
subsequent screening and scoring steps proceeded quicker,
since fewer compounds had to be screened. The subsequent
steps, proteochemometrics (PCM)9 and structure-based
modeling, were carried out in parallel. Additionally, QSAR
models were constructed for the remaining kinases simulta-
neously. These QSAR models were compared to the more
advanced PCM models to select the best approach for scoring.
The performances of these QSAR models are included in
Table 1.
The PCM models that were created were applied solely for
the purpose of scoring and not as a filtering step. PIK3CA was
excluded from modeling, as insufficient data was available to
build and validate the models. The PCM models were
constructed for each kinase separately and were based on the
particular kinase and its L4 level family members as annotated
in ChEMBL.18 In addition to the compound descriptors used
in QSAR modeling (FCFP4 fingerprints and physicochemical
properties), the PCM models included protein descriptors that
were based on a full kinome sequence alignment (see Methods
for details). Initial PCM models were trained using default
random forest settings: 300 trees, log2(m) features at every
node in the tree, no maximum tree depth, a minimum of 2
samples to consider a node for splitting, and bootstrap enabled.
This resulted in an overall performance of MCC 0.22 and
ROC 0.69 (average over all panel kinases). Since the PCM
models were intended for scoring of compounds, the models
were optimized to enhance predictive performance. Optimal
settings were explored by tuning hyperparameters with random
search, a basic approach to automated machine learning.19
Approximately 500 random forest models were trained during
optimization, resulting in the best model with performance
MCC 0.25 and ROC 0.74 and the following settings: 300 trees
(fixed) with 43 features at every node in the tree, a maximum
tree depth of 99, a minimum of 12 samples to consider a node
for splitting, and bootstrapping disabled. The performance of
the QSAR and PCM models per kinase are shown in Table 1.
Predictions for most kinases were comparable between
QSAR and PCM modeling. However, for target PAK3, PCM
clearly outperformed QSAR with MCC difference 0.18 and
ROC difference 0.20. MCC could not be calculated for ERK8
because of a small data set and, consequently, a lack of a
predicted class (total number of compounds for ERK8 is 332).
Using QSAR, the MCC displays a negative correlation for
ERK8 (−0.12), which is also reflected by the ROC score that is
worse than random (ROC < 0.5). PDK1 has high early
enrichment (BEDROC (Boltzmann-enhanced discrimination
of the receiver operating characteristic)) with both QSAR and
PCM. Although overall enrichment (ROC) for PDK1 is lower
than the early enrichments, it is still good with ROC 0.71
(QSAR) and 0.72 (PCM). The average over all targets shows
that PCM predicts slightly better than QSAR, with a similar
MCC score of 0.25, but higher (BED)ROC scores: differences
BEDROC = 0.06 and ROC = 0.06. Moreover, the nature of
PCM models allows for extrapolation of bioactivities from
related kinases to the target of interest. Therefore, it was
hypothesized that the PCM models will perform better than
QSAR models when applied to a more diverse chemical data
set such as the virtual screening sets. The performances of the
PCM models of the main on-targets AURKA and PAK1 were
higher than the average performance over all targets. However,
main on-target RET had a PCM MCC value (0.15) that was
lower than average (0.25). Nevertheless, (BED)ROC scores
were higher than the average: RET BEDROC 0.64, RET ROC
0.76, average BEDROC 0.58, and average ROC 0.74.
Moreover, all RET scores were better than random indicating
the predictive power of the model.
The settings that corresponded to the best performing
model in 4-fold cross-validation were applied to train PCM
models on the full data set per kinase (including test set in
Journal of Chemical Information and Modeling pubs.acs.org/jcim Article
https://dx.doi.org/10.1021/acs.jcim.9b01204
J. Chem. Inf. Model. XXXX, XXX, XXX−XXX
C
training). The models were applied to score all the virtual
screening compounds that passed the filtering step using
QSAR models.
Structure-Based Models. Structure-based scoring was
performed in addition to scoring of compounds using the
PCM models. For many kinases, multiple crystal structures
have been deposited in the PDB, and it is often not obvious
which crystal structure should be used prospectively. There-
fore, we performed a rigorous benchmark to determine the
best enriching crystal structure. The number of validated
crystal structures for all targets ranged from 1 to 135, excluding
ERK8 and PAK3 for which no crystal structures were available
at the time (December 2017). The crystal structures that were
deemed suitable for virtual screening were X-ray protein
structures that contained a cocrystallized orthosteric ligand. A
total of 499 crystal structures were benchmarked using
corresponding compound benchmark sets that were composed
for each target separately. The benchmark sets containing
active compounds, inactive compounds, and decoys, were
docked into the orthosteric binding pockets, from which a
docking score was derived for each compound. The decoys
were considered as inactive compounds when calculating
actives enrichment for each crystal structure. Enrichment was
calculated based on best docking score per compound. It was
observed that actives enrichment varied greatly between
different structures of the same kinase: ROC ranging from
0.58 (PDB 2IVS) to 0.77 (2IVU) for RET, 0.47 (5OSF) to
0.80 (2XNG and 4O0W) for AURKA, and 0.65 (3Q4Z and
4O0T) to 0.95 (5IME) for PAK1 (performances for every
kinase, see Table S3). The models per target were ranked
based on the sum of the overall (ROC) and early enrichment
(BEDROC, α = 160.9). Models with a score ROC+BEDROC
≥ 1 (e.g., ROC 0.40 + BEDROC 0.60) were considered
sufficient for prediction of active compounds.
Kinases LKB1 and MKNK1 only had a few crystal structures
available (1 and 2 structures, respectively) of which perform-
ance was low (ROC + BEDROC: 0.50 and 0.72, respectively).
Moreover, kinase S6K of which 18 structures were available,
only reached maximum performance of ROC+BEDROC 0.80.
Therefore, additional protein structures were created for these
kinases by application of induced-fit docking. In contrast to
docking, induced-fit docking accommodates the ligand and
additionally reorientates the side chains of binding pocket
residues. This allows the residues to change conformation in
order for the ligand to fit into the binding pocket. Five ligands
for each LKB1, MKNK1, and S6K, were docked with induced-
fit docking into the respective binding pocket. Subsequently,
the ligands were removed from the protein, keeping only the
altered protein structures. This resulted in 95 additional
protein structures for LKB1, 44 for MKNK1, and 74 for S6K.
These additional structures were validated using the same
benchmark sets as used for the initial structures. The protein
structures that were created using induced-fit docking varied in
performance from ROC+BEDROC 0.27 to 1.07. For all three
kinases, an induced-fit structure was generated that out-
performed the initial crystal structure. The best performance
for LKB1 was ROC+BEDROC 0.99, for MKNK1 it was 1.07,
and for S6K it was 0.97. The protein structures resulting from
induced-fit docking are available at dx.doi.org/10.4121/
uuid:9e61b6a6-88e5-4a18-ba19-dbf1bbdd656a.
On the basis of the docking performances of all models, five
protein structures per target were selected for structural
protein−ligand interaction fingerprints (SPLIF)20 calculations.
With SPLIF, interactions between the binding pocket residues
and (docked) ligand are calculated, resulting in a SPLIF score
that indicates the similarity between the interactions of the
(docked) ligand compared to a reference compound. In this
case, the reference compound consists of the cocrystallized
ligand in the corresponding structure. The structures for SPLIF
calculations were selected based on diversity of the cocrystal-
lized ligands per kinase. The diversity of these ligands was
assessed by clustering the ligands using affinity propagation
clustering.21 The cluster centers of the structures with highest
ROC+BEDROC in docking were selected as reference.
Consequently, the corresponding protein structures and
docked benchmark set poses were thus used in SPLIF
calculations. The SPLIF similarity scores for each benchmark
compound were used to calculate actives enrichment based on
SPLIFs. Especially for MKNK1 actives enrichment increased
significantly compared to enrichment based on docking scores:
ROC+BEDROC SPLIF 1.57 versus ROC+BEDROC docking
1.07. On the basis of early enrichment, BEDROC (α = 160.9),
the performance using SPLIF scores increased for 9 of 13
kinases (Figure 2). However, for targets BRAF, PDK1, PAK1,
and FGFR1 docking scores enriched (BEDROC (α = 160.9))
better than SPLIF scores.
An ensemble score was constituted, which combined
docking and SPLIF scores. This ensemble score, the Z2
score,22 was based on only docking scores, only SPLIF scores,
or a combination of docking and SPLIF scores (see Methods
for details). Prior to calculation of Z2-scores, the docking and
SPLIF scores were normalized to Z-scores (more negative Z-
score means better binding). This normalization was done with
respect to the actives from the benchmark set for a given
kinase. The early enrichments of active compounds based on
Z2-scoring increased performance for 10 of the 13 targets
Figure 2. Early enrichment of actives, BEDROC (α = 160.9), per
crystal structure for each target. Enrichment reached by docking
scores (blue), SPLIF scores (orange), and Z2-scores (red), are shown
for all 13 kinases that had a crystal structure available. Numbers on
top indicate the number of crystal structures for each kinase.
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(Figure 2). The best (ensemble of) models per target are listed
in Table S5. The best performances of the main on-targets
RET, AURKA, and PAK1 were reached by Z2-scoring. The
performance of PAK1 was very good with BEDROC (α =
160.9) 0.97. However, it should be noted that the number of
compounds in this benchmark set was low due to lack of data
(63 active compounds, 10 inactive compounds and 3886
decoys). Therefore, this model may not be representative when
applied to a virtual screening set. The best BEDROC
performances of RET and AURKA were 0.56 and 0.52,
respectively. Furthermore, the overall performance for these
targets were good with ROC 0.85 for RET and ROC 0.82 for
AURKA.
Prospective Structure-Based Docking. The virtual
screening compounds resulting from QSAR filtering were
docked into the protein structures that resulted in the best
performances in benchmarking. Not the entire virtual screen-
ing set could be docked on all kinases because of time
constraints. Therefore the top 250 000 compounds for RET,
AURKA, and PAK1, with highest active-class probabilities,
were selected for docking. This included all active-predicted
compounds for RET and AURKA (167 828 for RET and 315
for AURKA), and additional, consecutively ranked compounds
that did not reach the QSAR activity threshold (active class
probability > 0.5). For PAK1, the top 250 000 compounds
were selected from a total of 298 163 active-predicted
compounds. Subsequently, the compounds were assigned a
structure-based Z2 score, with the exception of S6K, MKNK1,
and PDK1 for which SPLIF or docking score gave the best
BEDROC (α = 160.9) performance and thus Z2-scores were
replaced with the respective score. The best scoring method
for S6K underperformed with a BEDROC of 0.24. Although
this model was not discarded immediately, the poor perform-
ance was taken into account later when reliability weights were
assigned to the corresponding method and kinase.
Binding Pose Metadynamics. Binding pose metadynam-
ics23,24 was performed to rescore the docked poses and scores
of compounds. Since binding pose metadynamics is a time-
consuming modeling technique, only the main on-targets
(RET, AURKA, and PAK1) were subjected to this method.
Binding pose metadynamics measures the persistence of
ligand-protein interactions and the movements of the ligand’s
heavy atoms, which are sampled during variation of the
complex’s free energy states throughout the simulation. The
result of binding pose metadynamics is a metadynamics-
composition score. This composition score was calculated for
the top 100 compounds (based on docking score) from the
benchmark set of each included kinase. The docking scores
from which these top 100 compounds were chosen were
derived from a single protein structure per target to allow for
easy and direct comparison. The selected protein structures
had the best actives enrichment based on docking and included
2IVU for RET, 2BMC for AURKA, and 4EQC for PAK1. The
composition score was added to the docking score, resulting in
a combined score. The actives enrichment for the targets was
re-evaluated using this new score. It was observed that
performance (based on the top 100 compounds) of PAK1
did not increase (ROC+BEDROC difference 0.01). However,
actives enrichment for RET and AURKA increased with
performances (ROC+BEDROC) 1.27 for RET and 1.76 for
AURKA, compared to initial (docking) performance of 1.26
for RET and 0.77 for AURKA. Therefore, for RET and
AURKA the docking scores of virtual screening compounds
were rescored with metadynamics-composition scores, result-
ing in an indirect reranking of the top 100 virtual screening
compounds, which was based on Z2 scores.
Polypharmacology Ranking of Compounds. The
virtual screening compounds were scored with both a statistical
model score (PCM score) and structure-based score. A final
compound rank per target was constituted by adding a weight
to the predictions made by statistical models and structure-
based models (Table 2). The ranking order of compounds for
off-targets, that is, kinase compounds should not interact with,
was reversed: ranking compounds with high predicted activity
as lowest, and compounds with worst predicted activity as
highest. The weights of the statistical PCM model were based
on the ROC score corrected for the size of the training data set
per target. The structure-based models were considered to be
better suited to select novel chemistry and were therefore
assigned higher weights than the PCM model weights:
structure-based models were attributed more weight compared
to equally performing PCM models (same ROC). The weights
of the structure-based models were calculated by taking the
sum of BEDROC+ROC. These weights were reduced by
penalizing the models when induced-fit structures were used
and when the numbers of compounds in the benchmark sets
were insufficient (for details see Methods). The weights were
subsequently used to rank the compounds per target:
Structure-based Z2-scores were multiplied by the structure-
based weight, PCM predicted class probability was multiplied
by the statistical model weight, and as final step the derived
scores were summed up to retrieve a final rank per target.
On the basis of the overall target weights (Table 2),
predictions for kinases LKB1, ERK8, PAK3, TAK1, and
Table 2. Weights Assigned to Each Target Per Modeling Technique
panel 1 kinases
on-target off-target
RET BRAF SRC S6K MKNK1 TTK ERK8 PDK1 PAK3
PCM 0.54 0.14 0.90 0.67 0.13 0.41 −0.02 0.35 0.70
structure based 1.44 1.66 1.56 0.48 1.42 1.79 n.a. 1.45 n.a.
total 1.98 1.80 2.46 1.15 1.55 2.20 −0.02 1.80 0.70
panel 2 kinases
on-target off-target
AURKA PAK1 FGFR1 LKB1 TAK1 PIK3CA PAK3
PCM 0.93 0.50 0.98 0.28 0.16 n.a. 0.70
structure based 1.34 1.23 1.62 0.04 0.46 0.97 n.a.
total 2.27 1.73 2.60 0.32 0.62 0.97 0.70
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PIK3CA, were not very reliable. However, predictions for the
more important main on-targets RET, AURKA, and PAK1
were considered to be reliable. The workflow was evaluated by
the selection and experimental validation of compounds for
one of the main on-targets: RET. The consensus approach was
used to select 15 highly ranked virtual screening compounds
for RET (all compounds had PCM score >0.4 and structure-
based score Z2 < 0), which were validated in vitro. Moreover,
the performance of the different approaches was compared on
the RET models by additionally selecting compounds based on
the predictions of only statistical models, and only structure-
based models.
Experimental Validation. The models were evaluated by
experimental validation of predicted actives for RET kinase. A
total selection of 46 compounds was purchased and validated
for RET inhibition. These compounds were selected by
different criteria: 6 compounds based on predicted activity by
QSAR and PCM modeling, 25 compounds based on structure-
based docking (including rescoring by binding pose metady-
namics) and SPLIF scoring, and 15 compounds based on
consensus scoring of statistical and structure-based models.
Compounds that were selected using only statistical models
satisfied the set active-class threshold criteria of both QSAR
(active probability > 0.6) and PCM (active probability > 0.5).
The structure-based thresholds were docking score < −8 and
SPLIF score >0.25. Additionally, structure-based compounds
with a docking score < −10 were selected that did not
necessarily adhere to the SPLIF score criteria. Furthermore,
compounds that were selected based on consensus scoring
fitted the following thresholds: statistical predictions PCM >
0.4, and structure-based score Z2 < 0. The compounds that
were selected based on structure-based predictions or with
consensus scoring were additionally inspected visually by
checking the 3D docking pose and interaction with the hinge
region.
The 46 compounds were first tested using single point
measurements at two concentrations: 10 and 0.1 μM (Table
S6). The top ten compounds showing RET inhibition (RET
activity < 80%, concentration 10 μM), were based on either
consensus scoring or structure-based scoring. None of these
compounds was from statistical scoring only. Five compounds
showed inhibitory activity (RET activity < 60%) for RET at a
concentration of 10 μM, of which one compound also showed
slight RET inhibition at concentration 0.1 μM (RET activity <
100%). The activities of the four most potent hits were
assessed more accurately by a potency determination in
triplicate, yielding pIC50 values. The inhibitors were modestly
active. ZINC33008650 was the best inhibitor with a pIC50 of
5.1 ± 0.1, followed by ZINC72312837 (pIC50 4.6 ± 0.2),
ZINC12324934 (pIC50 4.6 ± 0.2), and ZINC9518200 (pIC50
4.0 ± 0.2). The docked pose of ZINC12324934 in RET
suggests that the compound is an orthosteric binder with
potential to bind to the hinge region, as evidenced by a
hydrogen bond interaction with the backbone of Ala807
(Figure 3). Additional hydrogen bonds are observed between
the ligand and Glu775, Ser891, and Lys728. The docked poses
of all four inhibitors are included in Supplementary file S7.
Although the inhibitors showed modest activity, their chemical
diversity compared to known RET inhibitors was high since
the compounds were prefiltered on novelty by selecting on
Tanimoto similarity < 0.4 (compared to inhibitors with
pChEMBL value ≥ 5).
Bioactivity Spectra Prediction. The bioactivity profile of
the five most active inhibitors for RET was predicted for all
kinases in the panel. The bioactivity spectra for both on- and
off-targets are shown in Table 3, where positive values indicate
binding and values below and including zero indicate no
binding. On the basis of the entire predicted bioactivity
spectra, the most potent RET inhibitors comply better with
inactivity on off-targets than activity on on-targets. However,
the predictions are not equally reliable for each kinase (based
on the previously assessed weights shown in Table 2).
Nevertheless, assuming that the predictions of the kinases
that scored equally well or better compared to RET (weight
1.98) are the most accurate, conclusions can be drawn for on-
target SRC and off-target TTK (weights 2.46 and 2.20,
respectively). Although the RET inhibitors were not predicted
active for SRC, inactivity was predicted for off-target TTK.
The compounds were selected based on bioactivity for RET,
and as a result may not show optimal bioactivity spectra.
However, the novelty filter to which the compounds were
subjected prior to virtual screening included all of the kinases
in the panel (as opposed to only RET). Therefore, all
predicted interactions might indicate novel starting points for
future research.
Manual Inspection of Hits. The four most potent hit
compounds resulting from virtual screening and experimental
validation were inspected based on their novelty and
patentability. Novelty was re-evaluated by similarity searching
(Tanimoto ECFP6) on a more strict threshold for RET
compounds (pChEMBL ≥ 4) in the most recent version of
ChEMBL (version 25) and patentability was checked in
SureChEMBL25 (similarity > 0.9). The most similar RET
actives were CHEMBL1979093 for ZINC33008650 (similarity
0.24, RET pChEMBL 7.2), CHEMBL1983715 for
ZINC12324934 (similarity 0.18, RET pChEMBL 6.9),
CHEMBL1977134 for ZINC9518200 (similarity 0.20, RET
pChEMBL 8.4), and CHEMBL1965570 for ZINC72312837
(similarity 0.29, RET pChEMBL 7.6) (Table 4). None of the
compounds was listed as patented in SureChEMBL.
Figure 3. ZINC12324934 (green) docked into the orthosteric
binding pocket of RET (orange) (PDB 2IVU). Hydrogen bonds
are displayed as yellow dotted lines.
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Additionally, novelty of the chemical scaffolds was checked,
which were compared based on Bemis-Murcko26 scaffold trees
with known active compounds for RET in ChEMBL. None of
the four hit compounds was clustered in the same scaffold
cluster as a known active, supporting the novelty of the
inhibitors. Although the hit compounds were identified as
modestly active binders, further SAR around these inhibitors
may yield more potent derivatives. The novel scaffolds may be
explored along different vectors to enhance affinity of the
ligands and may reveal a new chemical space for RET
inhibitors.
■ DISCUSSION
An elaborate virtual screening process was constituted in which
both statistical and structure-based models were applied that
were all carefully tuned and validated. Statistical models were
validated using as many compound data as possible, with
attention paid to chemical diversity of the subsets in cross-
validation. Structure-based models were slower than the
statistical models and therefore smaller benchmark sets were
used for validation of these models. These benchmark sets
were composed of diverse actives to cover a large chemical
space, irrespective of the smaller size of the data set. By
application of statistical QSAR models and structure-based
docking successively, computational time was used efficiently
in virtual screening: compounds that had the least predicted
activity probability for the main on-targets based on the QSAR
models were excluded from docking. The consensus scoring
approach, in which statistical PCM scores were combined with
structure-based predictions, resulted in sets of active-predicted
compounds per kinase. However, compounds were excluded
from bioactivity modeling if the respective kinase had a poor
reliability weight. This reliability weight was based on the
performances per model per target derived from the
benchmarking steps.
It was observed that the lack of compound data resulted in
lower performance of statistical models in particular, as seen
for kinase ERK8. Although structure-based models also
performed worse for targets with less compound data and
less crystal structures, this could partially be resolved by
creation of additional protein structures using induced-fit
docking and alternative scoring with SPLIF and Z2. However,
alternate structures could also have be created using more
elaborate ligand-protein sampling methods such as molecular
dynamics.27 Interestingly, performance between different
structures of the same kinase varied greatly, rendering the
benchmarking of multiple protein structures necessary.
On the basis of the final reliability scores, kinases RET,
BRAF, SRC, MKNK1, TTK, PDK1, AURKA, PAK1, and
FGFR1, are best used in bioactivity modeling, whereas
predictions for kinases S6K, ERK8, PAK3, LKB1, TAK1, and
PIK3CA, may not be accurate enough and thus should be
excluded for now. Although the models of the first kinases are
considered reliable, identification of compounds that fit the
desired bioactivity profiles on these targets remains challeng-
ing. Since hit rates are rarely 100%, compounds with a well-
predicted profile would need experimental validation. The hit
rate for the experimental validation for RET in this study was
11% over 46 compounds, using pIC50 ≥ 4 (or RET activity <
60% at a concentration of 10 μM) as a threshold for active
compounds. On the hypothesis that similar hit rates will be
achieved for the other kinases, the probability of a compound
being active on a number of kinases thus decreases with every
additional target. Therefore, the number of experimentally
validated compounds should be expanded, to increase the
chance of finding a compound that fully fits the desired
bioactivity profile.
Table 3. Predicted Bioactivity Spectra for the Panel 1 Kinases of the Five Most Potent RET Inhibitors
on-target off-target
compound RET BRAF SRC S6K MKNK1 TTK ERK8a PDK1 PAK3a
ZINC33008650 1 0 0 0 −2 −2 0 −2 0
ZINC12324934b 0 0 0 0 0 0 0 0 0
ZINC9518200 2 0 0 0 −1 −1 0 −1 0
ZINC72312837 2 0 0 0 −1 −1 0 −2 0
ZINC65184824 1 −1 0 0 −2 −1 0 −2 0
aPredictions based on limited structure-based data (no crystal structure available). bCompound was selected on RET docking score only; therefore,
no Z2 score was available for this compound and no structure-based weight could be assigned.
Table 4. Novel RET Inhibitors and Their Most Similar RET
Actives in ChEMBL Based on Tanimoto (ECFP6)
Journal of Chemical Information and Modeling pubs.acs.org/jcim Article
https://dx.doi.org/10.1021/acs.jcim.9b01204
J. Chem. Inf. Model. XXXX, XXX, XXX−XXX
G
The five hits that proved active on RET kinase were found
with either consensus scoring or structure-based modeling.
Although the number of compounds validated using statistical
models is smaller, it is plausible that statistical modeling by
itself is not a strong enough predictor to identify really novel
compounds.28 Since the virtual screening compounds were
prefiltered on novelty (Tanimoto ECFP6 < 0.4) with known
actives, the models were challenged with identification of
chemical dissimilar actives.29 This is a difficult task for
statistical models as they rely on chemical patterns of known
actives, and therefore, dissimilar compounds may lie outside
the applicability domain of these models.29 To resolve this
issue, the chemical space can be expanded by addition of
chemical diversity.8 Although this requires biological experi-
ments to validate (in)activity of new compounds, an iterative
screening approach may be applied to expand the chemical
space efficiently and cost-effectively.30 Nevertheless, identi-
fication of novel chemistry without the need for addition of
much experimental data may be achieved through structure-
based modeling, as these models are not particularly biased
toward known chemistry. Yet, bias in structure-based models
may indirectly be present, as the best performing protein
structures were based on enrichment of known actives.
Nevertheless, this is a minor issue compared to the relatively
limited scope and bias of chemical space of statistical models.
The applied workflow in this study employs a filtering step
through which compounds are discarded that were categorized
as inactive by statistical QSAR models. On the basis of the
previous statement on applicability domain, it is assumed good
inhibitors can be wrongly categorized as “inactive” and
neglected by the statistical model. One might reason that
docking of all compounds may be a more effective method to
identify novel inhibitors, as docking of 170 million compounds
in proteins AmpC β-lactamase and the D4 dopamine receptor
resulted in novel chemical scaffolds.31 However, docking of
millions of compounds on multiple proteins is a very time-
consuming task (∼170 000 compounds per day for 1 RET
crystal structure (24 cores)), which is unfeasible without
significant computational resources. Thus, considering the
scope of the task, the possibility that the QSAR models discard
“good” compounds is accepted, as the QSAR models decrease
the runtime of the workflow and make the task comprehensive.
As a final remark, it should be mentioned that the workflow
applied to kinases did not implement orthosteric or allosteric
binding of compounds. Therefore, inhibitors were not tuned to
bind to the DFG-in or DFG-out kinase conformation, a
conformational change that influences inhibitor binding
greatly.32 Although structure-based docking was focused on
the ATP-binding pocket, the most optimal crystal structures
were selected based on benchmark sets that were not filtered
for DFG-out and allosteric binders. As a consequence, crystal
structures may have been selected that enriched DFG-out
binders better than DFG-in binders. Moreover, since the
statistical models were trained on sets that were not filtered for
DFG-out binders, these models were also not able to
distinguish DFG-in from DFG-out binders. As a result, it is
undetermined whether the five hits from the screening
workflow bind to the DFG-in conformation of RET. The
docked poses of the hits do not constitute optimal hinge-
binding, suggesting that it is plausible that they may be DFG-
out binders. Moreover, two of the five most potent hit
compounds contained a urea-motif, a motif that is often
associated with DFG-out binders.32,33 To capture the binding
type of compounds, machine learning models could be used to
predict the type of compound as an additional score,
something that will be considered for future work.34,35
■ CONCLUSION
An extensive workflow was designed to predict compound
activity in kinases and to model the compounds’ bioactivity
spectra in kinases. The workflow can easily be expanded to
other targets as well. By combining statistical and structure-
based modeling, processing speed was optimized, while the
accuracy of predictions was preserved. Every single kinase
target was validated separately, which enabled reliability
weights to be assigned to the predictions for every target.
The workflow was experimentally validated by testing
predictions made for RET kinase, a target with a good
reliability score. A selection of 46 compounds was tested in
vitro, of which 5 compounds showed RET inhibition (activity
< 60%) at a concentration of 10 μM. The four most potent
inhibitors had pIC50 values ranging from 4.0 to 5.1. The
Tanimoto similarities (ECFP6) of these inhibitors with known
RET actives was ≤0.29. Moreover, the compounds contained
unique chemical scaffolds, underscoring the true novelty of
these inhibitors.
■ METHODS
Data Set Statistical Models. Training and validation sets
for statistical models were constituted from compound
information derived from ChEMBL (version 23),11 publicly
available sets from Eidogen,12 and ExCAPE-DB.13 The
compounds with experimental bioactivity for any kinase were
filtered on molecular weight < 700, duplicates were removed,
and compounds were standardized using BIOVIA Pipeline
Pilot 2016:36 salts were removed, largest fragment was kept,
stereochemistry and π-systems were standardized, and charges
were neutralized. The resulting set contained 512 kinases and
123 246 bioactivities. For training and validation of the
classification models the threshold for “active” compounds
was set at pChEMBL/pKi/pIC50/pEC50 ≥ 6.5 as we did
previously.37 Compounds that did not reach this threshold
were termed “inactive”. All compounds per target were divided
into five subsets using clustering with the Cluster Molecules
component (FCFP4 clustering) in Pipeline Pilot 2016.
Compounds were clustered into five clusters per each kinase
family (same L2 level in ChEMBL). First, compounds were
separated based on activity (active when pChEMBL > 6.5) and
then clustered into five clusters, after which active and inactive
compounds were combined again. To ensure that every panel
kinase was represented in each cluster, clustering into five
clusters was done in two steps: the panel kinase was clustered
first, followed by coclustering of compounds from related
kinases into the same cluster. The biggest cluster, or subset,
was used as fixed training set, while the other four subsets were
rotationally used as test or training set in 4-fold cross-
validation. Data sets used in QSAR modeling only contained
information on the respective kinase. In PCM modeling,
additionally data of related kinases was included based on L4
classification in ChEMBL.
Data Set Structure-Based Docking. For each kinase
target, with the exception of PAK3 and ERK8 because of lack
of a crystal structure, a benchmark set was created to validate
structure-based docking for each target. The benchmarking set
for structure-based docking included active compounds,
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inactive compounds, and decoy compounds, which were
derived from ChEMBL (version 23) and the DUD-e Web
server.15 Compounds with reported pChEMBL value for the
challenge kinases, with confidence score 9, assay type B, and
molecular weight <550, were standardized using BIOVIA
Pipeline Pilot 201636 by removing salts and keeping the largest
fragment. An activity gap was realized to better distinguish
active and inactive compounds: compounds with a pChEMBL
value >6.5 were assigned the label “active”, and compounds
with a pChEMBL value >4 and <5.5 were labeled “inactive”.
Compounds with pChEMBL value ≤4 were excluded as
inactive compounds to limit the number of inactives.
Exceptions in the thresholds were made for activity labeling
of compounds for targets RET and MKNK1: for RET
compounds were labeled as inactive when pChEMBL value
>4.5 and <6.5, and for MKNK1 compounds were defined as
active when pChEMBL value >6 to increase the fraction of
active compounds. The thresholds used for RET were not
intended to alter the number of (in)active compounds; RET
was used as exploratory case and therefore for this kinase
“initial” thresholds were used. However, the “general”
threshold for all kinases was adapted since this yielded
increased performance.
Scaffold trees were generated for the compounds based on
Bemis−Murcko scaffolds26 and the compound with the highest
pChEMBL value per scaffold class, per activity class, per
kinase, was kept. Compounds labeled as active were clustered
into 100 clusters using the Cluster Molecules component (k-
means) in BIOVIA Pipeline Pilot 2016. From the resulting
clusters, only the cluster centers were kept. Kinases that had
less than 100 active compounds available were excluded from
this clustering step. The resulting active compound sets of
maximum 100 compounds per kinase were used to generate
decoys for each target kinase using the DUD-e Web server. For
target PIK3CA decoys were generated based on only 80% of
the active molecules as DUD-e decoy generation failed for the
remaining fraction. The decoys were considered as inactive
compounds when used in model validation. The collected
actives, inactives, and decoys were prepared for docking using
LigPrep from Schrödinger.23
Screening Data Set. Compounds for virtual screening
were extracted from the ZINC15 compound library.16 These
compounds were selected based on “in stock” status and were
filtered on a maximum of one Lipinski’s rule of five violation.
Additionally, the screening set was filtered on novelty by only
including compounds with Tanimoto similarity (ECFP6) < 0.4
compared to known “active” compounds (pChEMBL value ≥
5) in ChEMBL (version 23) for the kinases of the respective
panel. For panel 2, covering AURKA, PAK1, FGFR1, LKB1,
PAK3, TAK1, and PIK3CA, the screening set was additionally
filtered on PSA < 75 to allow permeability of the blood−brain
barrier. The compounds in the screening data set were
additionally prepared for structure-based docking by using
LigPrep.
Statistical ModelingQSAR. Single-target QSAR models
were constructed for the main on-target kinases RET, AURKA,
and PAK1. QSARs were built using BIOVIA Pipeline Pilot
2016 (version 18.0.1.1604). Models were trained on
compound descriptors FCFP4 (3000 most frequent bits) and
86 physicochemical descriptors (S1). The following settings
were applied in training categorical Random Forest QSAR
models: 1000 trees, log2(m) number of descriptors, equalized
class sizes, and seed 12345. The classification threshold for
active compounds was set at pChEMBL > 6.5.
Statistical ModelingPCM. PCM modeling was per-
formed on all 512 kinases in the statistical modeling data set. A
multitarget PCM model was constructed using a random forest
classifier in scikit-learn.38 Compound descriptors were the
same as used in QSAR modeling. Protein descriptors were
calculated based on full sequence alignment derived from
kinase.com (with a total of 1567 alignment positions including
gaps).39,40 The residues in the alignment were converted to
three z-scales and an additional mean value for each of the
three z-scales was added per sequence, resulting in a total of
4704 protein descriptors per kinase. Gaps were included in
these descriptors, and were assigned a value of “0” for all three
z-scales as was done previously.41,42
The random forest model was of high complexity because of
the high dimensionality of the data, which includes the
compounds’ physiochemical properties, FCFP4 descriptors,
and protein descriptors. The complexity of the random forest
models was reduced by imposing constraints on parameters,
such as the number of trees and maximum depth of the trees.
The hyperparameters of the random forest model were
optimized by utilizing random search, which evaluates the
performance of the algorithm using different and randomly
chosen configurations with cross-validation. Random search
can be considered a simple form of automated machine
learning19,43 and has been shown to outperform other basic
methods of hyperparameter optimization, such as grid
search.44 Approximately 500 random configurations were
evaluated, resulting in an improvement of on average 7%
AUROC over the default configuration (300 trees, log2(m)
features at every node in the tree, no maximum tree depth, a
minimum of 2 samples to consider a node for splitting, and
bootstrap enabled) in 4-fold cross-validation. The settings that
corresponded with the best model in random parameter
optimization were applied in model training on the full data
set, which was used in virtual screening. The final model
consisted of 300 trees (fixed) with 43 features at every node in
the tree, a maximum tree depth of 99, a minimum of 12
samples to consider a node for splitting, and bootstrapping
disabled.
Structure-Based Docking. X-ray structures of all
challenge proteins were extracted from the PDB45 (except
for ERK8 and PAK3 as no structure was available at the time).
Crystal structures lacking cocrystallized orthosteric small-
molecule ligands were discarded. The remaining structures
were prepared for docking with the Protein Preparation tool
from the Schrödinger 2017-4 suite after removing any other
components than the protein, orthosteric ligand, and binding
pocket ions. The “add missing side chains” option was used,
waters were removed, hydrogens were added, and disulfide
bonds were created. The crystal structures were superposed
per target and cocrystallized ligands were removed from the
binding site. The grid for docking was determined for each
target by the center of one of the cocrystallized ligands (box
size xyz = 35 Å). Compounds were docked into the binding
pocket using the Schrödinger 2017-4 suite23 and the OPLS3
force field46 with standard precision (SP) and standard
settings. A maximum of ten poses per compound (per target)
was generated.
Induced-Fit Docking. Induced-fit docking, as imple-
mented in the Schrödinger 2017-4 suite,23 was applied to
kinases LKB1, S6K, and MKNK1. These kinases showed poor
Journal of Chemical Information and Modeling pubs.acs.org/jcim Article
https://dx.doi.org/10.1021/acs.jcim.9b01204
J. Chem. Inf. Model. XXXX, XXX, XXX−XXX
I
enrichment of actives when docked into the available crystal
structures (sum of ROC and BEDROC < 1). For S6K five
active compounds, for MKNK1 ten active compounds, and for
LKB1 six active compounds were docked using induced-fit
docking (see Table S8 for list of compounds). The crystal
structures selected for induced-fit docking were 2HW6 for
MKNK1, 2WTK for LKB1, and 3WF5, 3A62, and 4RLO for
S6K. The resulting protein conformations were used as
alternative protein structures in addition to the original crystal
structures.
Structural Protein−Ligand Interaction Fingerprints
(SPLIFs). Structural protein−ligand interaction fingerprints
(SPLIFs)47 were calculated for a maximum of ten poses per
compound that were retrieved from structure-based docking.
The cocrystallized ligands of the protein structures were used
as reference in SPLIF calculations to derive Tanimoto-like
SPLIF scores. Five protein structures per kinase were selected
for SPLIF generation. These structures were selected based on
diversity of their cocrystallized ligands and best active-
enrichment based on docking scores. The diversity of the
cocrystallized ligands was assessed using affinity propagation
clustering based on FCFP6 similarity.6 One protein structure
was selected from every corresponding cluster based on best
docking score performance until a maximum of five protein
structures was reached. Subsequently, Tanimoto-like SPLIF
scores were calculated for the compounds in the benchmark
sets for each of the selected protein structures. For each
compound (maximum 10 poses) the best SPLIF score was
used to calculate actives enrichment based on SPLIF scores.
For RET and PIK3CA exceptions were made in the
selection of benchmark proteins for SPLIF because only four
and three clusters were generated, respectively. Therefore,
similar cocrystallized ligands and their corresponding proteins
were also selected to get a total of five protein structures per
target. Furthermore, for RET structure 2IVV instead of the
cocrystallized ligand, CHEMBL3775169 was used as a
reference.
Binding Pose Metadynamics. A metadynamics-compo-
sition score10 was calculated with the binding pose
metadynamics tool in the Schrödinger 2017-4 suite,23 for
compounds and poses derived from structure-based docking.
The top 100 compounds for RET (PDB 2IVU) and AURKA
(PDB 2BMC) were selected, based on best docking scores.
The protein structures were prepared for metadynamics
simulations by capping the termini and the run time of each
simulation was set at 10 ns. The resulting metadynamics-
composition scores were added to the existing docking scores
to rerank the top 100 compounds in the benchmark set and to
rerank the top 100 compounds in the screening set.
Ensemble Scoring in Structure-Based Modeling. For
every target, protein models for virtual screening were selected
based on ensemble scoring of docking and SPLIF scores. The
combination, or ensemble, of protein models that resulted in
the best actives enrichment was used in virtual screening. The
validated ensembles were based on docking scores of the top
five enriching models and all five SPLIF models per target.
Different ensembles were tested for each target including:
docking scores only, SPLIF scores only, and docking and
SPLIF scores combined. The performances of the ensembles
were evaluated using Z2-scoring by averaging over the top two
Z-scores.47 Prior to ensembling, the Z-scores per compound
were normalized toward the actives from the respective
benchmark set. Docking scores were normalized to Z-scores
by subtracting the mean docking score (mean over docking
scores from all actives in the benchmark set) from the docking
score of the test compound, and subsequently dividing by the
standard deviation of the (benchmark) actives’ docking scores.
The same approach was used in normalization of SPLIF scores
to Z-scores. However, the SPLIF scores were first multiplied by
−1 to change the vector into the same direction as the docking
scores (better binder, more negative score).
Compound Ranking Per Target. The compounds in
virtual screening were ranked for ensembles of targets based on
the scores derived from PCM modeling and structure-based
ensemble score. The PCM predictions were given a confidence
weight between 0 and 1 based on the prediction performance
per target (with 0 being no confidence and 1 being highest
confidence). The confidence score for the PCM model could




max number of samples
PCM
= * − *
The PCM confidence score was based on the number of
compounds (of the corresponding target) in training and the
ROC score derived from 4-fold cross-validation: ROC * 2 − 1
(to normalize that 0.5 corresponds with a weight of 0 and 1
corresponds with a weight of 1), multiplied by the weight
based on the number of samples for the target in the training
data (calculated as sqrt(number of samples)/sqrt(maximum
number of samples).
The weights of the structure-based predictions were
calculated by taking the total sum of ROC and BEDROC
per target,48 consequently giving the structure-based predic-
tions more weight than the statistical PCM model predictions.
However, structure-based models were penalized (by multi-
plying with 0.5) when induced-fit models were created for the
kinase. Moreover, kinases containing less than 100 actives in
the benchmark set were penalized by multiplying the structure-
based weight with the fraction of number of actives (with a
fraction of 1 being 100 actives, and a fraction of 0.1 being 10
actives).
Finally, the obtained weights for PCM and structure-based
models were applied in calculating the compound rank per
kinase.
Z
compound rank confidence weight








Compound predictions were multiplied by the subtotal weights
and summed up (statistical model weight * statistical PCM
prediction + structure-based model weight * structure-based
Z2 score), resulting in a final compound rank per target.
Protein Kinase Assay. A selection of 46 compounds was
experimentally validated for inhibitory activity against RET.
The compounds were ordered via Mcule Inc.49 (Budapest)
and purchased from ChemBridge, ChemDiv, ChemScene,
Enamine, Life Chemicals, and Vitas M Chemical Limited. The
assays were performed by ProQinase GmbH,50 Germany. First,
the compounds were tested (n = 1) at final assay
concentrations 10 and 0.1 μM. The five resulting hits (<60%
remaining RET activity at concentration 10 μM) were re-
evaluated by determination of IC50 values (n = 3). RET WT
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activity was measured using a radiometric protein kinase assay
(33PanQinase Activity Assay). All kinase assays were performed
in 96-well FlashPlates from PerkinElmer (Boston, MA, USA)
in a 50 mL reaction volume. The reaction cocktail was pipetted
in 4 steps in the following order: (1) 20 mL of assay buffer, (2)
5 mL of ATP solution (in H2O), (3) 5 mL of test compound
(in 10% DMSO), and (4) 20 μL enzyme/substrate mix. The
assay for all protein kinases contained 70 mM HEPES−NaOH
pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 mM Na-orthovanadate,
1.2 mM DTT, 50 μg/mL PEG20000, 1 μM ATP, [γ-33P]-ATP
(approximately 1.91 × 1005 cpm per well), 40 ng/50 μL of
protein kinase, and 0.125 μg/50 μL of poly(Glu, Tyr)4:1
substrate. The reaction cocktails were incubated at 30 °C for
60 min. The reaction was stopped with 50 mL of 2% (v/v)
H3PO4; the plates were aspirated and washed two times with
200 mL 0.9% (w/v) NaCl. Incorporation of 33Pi was




The Supporting Information is available free of charge at
https://pubs.acs.org/doi/10.1021/acs.jcim.9b01204.
List of 86 physicochemical descriptors (XLSX)
Structure-based benchmark performance for crystal
structures of every panel kinase (XLSX)
Selected structure-based models per target (XLSX)
Bioactivities of 46 compounds validated for RET activity
(XLSX)
Docked poses of the four most potent hit compounds
(ZIP)
List of compounds used to generate structures for S6K,
MKNK1, and LKB1, with induced-fit docking (XLSX)
■ AUTHOR INFORMATION
Corresponding Author
Gerard J. P. van Westen − Division of Drug Discovery &
Safety, Leiden Academic Centre for Drug Research, Leiden
University, 2333 CC Leiden, The Netherlands; orcid.org/
0000-0003-0717-1817; Email: gerard@lacdr.leidenuniv.nl
Authors
Lindsey Burggraaff − Division of Drug Discovery & Safety,
Leiden Academic Centre for Drug Research, Leiden University,
2333 CC Leiden, The Netherlands; orcid.org/0000-0002-
2442-0443
Eelke B. Lenselink − Division of Drug Discovery & Safety,
Leiden Academic Centre for Drug Research, Leiden University,
2333 CC Leiden, The Netherlands
Willem Jespers − Division of Drug Discovery & Safety, Leiden
Academic Centre for Drug Research, Leiden University, 2333
CC Leiden, The Netherlands; Department of Cell and
Molecular Biology, Uppsala University, Uppsala 75124,
Sweden; orcid.org/0000-0002-4951-9220
Jesper van Engelen − Department of Computer Science, Leiden
Institute of Advanced Computer Science, Leiden University,
2333 CA Leiden, The Netherlands
Brandon J. Bongers − Division of Drug Discovery & Safety,
Leiden Academic Centre for Drug Research, Leiden University,
2333 CC Leiden, The Netherlands
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